- Home
- SCNX vs MRNS Comparison
SCNX vs MRNS Comparison
Compare SCNX & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- MRNS
- Stock Information
- Founded
- SCNX 2010
- MRNS 2003
- Country
- SCNX United States
- MRNS United States
- Employees
- SCNX N/A
- MRNS N/A
- Industry
- SCNX Other Pharmaceuticals
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- MRNS Health Care
- Exchange
- SCNX Nasdaq
- MRNS Nasdaq
- Market Cap
- SCNX 33.6M
- MRNS 29.9M
- IPO Year
- SCNX 2020
- MRNS 2014
- Fundamental
- Price
- SCNX $3.01
- MRNS $0.55
- Analyst Decision
- SCNX
- MRNS Buy
- Analyst Count
- SCNX 0
- MRNS 12
- Target Price
- SCNX N/A
- MRNS $4.28
- AVG Volume (30 Days)
- SCNX 12.8K
- MRNS 1.2M
- Earning Date
- SCNX 02-18-2025
- MRNS 03-04-2025
- Dividend Yield
- SCNX N/A
- MRNS N/A
- EPS Growth
- SCNX N/A
- MRNS N/A
- EPS
- SCNX 3.55
- MRNS N/A
- Revenue
- SCNX N/A
- MRNS $31,466,000.00
- Revenue This Year
- SCNX $1,085.75
- MRNS $14.97
- Revenue Next Year
- SCNX N/A
- MRNS $57.65
- P/E Ratio
- SCNX $1.41
- MRNS N/A
- Revenue Growth
- SCNX 166.67
- MRNS 1.63
- 52 Week Low
- SCNX $3.05
- MRNS $0.22
- 52 Week High
- SCNX $44.56
- MRNS $10.50
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- MRNS 70.71
- Support Level
- SCNX N/A
- MRNS $0.54
- Resistance Level
- SCNX N/A
- MRNS $0.55
- Average True Range (ATR)
- SCNX 0.00
- MRNS 0.00
- MACD
- SCNX 0.00
- MRNS -0.01
- Stochastic Oscillator
- SCNX 0.00
- MRNS 100.00
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.